<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002145'>Frontotemporal dementia</z:hpo> (FTD) is a clinical phenotype of <z:hpo ids='HP_0000726'>dementia</z:hpo>, characterized by complex of clinical symptoms, including <z:hpo ids='HP_0000734'>disinhibition</z:hpo>, <z:e sem="disease" ids="C0235181" disease_type="Mental or Behavioral Dysfunction" abbrv="">character change</z:e>, increased appetite, sexual misconduct and language problems </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0751072" disease_type="Mental or Behavioral Dysfunction" abbrv="FTLD">Frontotemporal lobar degeneration</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FTLD</z:e>) is a pathological classification of <z:e sem="disease" ids="C0524851" disease_type="Disease or Syndrome" abbrv="">neurodegenerative disorder</z:e> and its core consists of <z:e sem="disease" ids="C0236642" disease_type="Disease or Syndrome" abbrv="">Pick's disease</z:e> (PiD) </plain></SENT>
<SENT sid="2" pm="."><plain>Historically, PiD was morphologically subclassified into three types, but recent immunocytochemical investigations defined type I as PiD with Pick bodies (three repeat <z:e sem="disease" ids="C0949664" disease_type="Disease or Syndrome" abbrv="">tauopathy</z:e>), type II as <z:e sem="disease" ids="C0393570" disease_type="Disease or Syndrome" abbrv="">corticobasal degeneration</z:e> (CBD, four repeat <z:e sem="disease" ids="C0949664" disease_type="Disease or Syndrome" abbrv="">tauopathy</z:e>) and type III as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FTLD</z:e> with ubiquitinated inclusions (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FTLD</z:e>-U) </plain></SENT>
<SENT sid="3" pm="."><plain>The recent progress provided an evidence that the majority of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FTLD</z:e>-U represented primary TDP 43 proteionopathy </plain></SENT>
<SENT sid="4" pm="."><plain>Three major clinical phenotypes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FTLD</z:e> consist of FTD, semantic <z:hpo ids='HP_0000726'>dementia</z:hpo> (SD) and progressive non-fluent <z:hpo ids='HP_0002381'>aphasia</z:hpo> (PNFA) </plain></SENT>
<SENT sid="5" pm="."><plain>Clinical and pathological correlative studies demonstrated that majority of the background pathology of FTD is PiD with Pick bodies, that of SD is <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FTLD</z:e>-U and that of PNFA is CBD, although there are too many exceptions </plain></SENT>
<SENT sid="6" pm="."><plain>Although FTD is one of the major clinical manifestations of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FTLD</z:e>, the most frequent pathological background of FTD is <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> (AD) </plain></SENT>
<SENT sid="7" pm="."><plain>The degenerative processes causing FTD symptoms include <z:hpo ids='HP_0000726'>dementia</z:hpo> with <z:hpo ids='HP_0100315'>Lewy bodies</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>), <z:e sem="disease" ids="C0038868" disease_type="Disease or Syndrome" abbrv="PSNP1">progressive supranuclear palsy</z:e> (PSP) and argyrophilic grain disease </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, vascular process such as <z:e sem="disease" ids="C0270786" disease_type="Disease or Syndrome" abbrv="">Binswanger disease</z:e> and inflammatory process such as <z:e sem="disease" ids="C0027927" disease_type="Disease or Syndrome" abbrv="">neurosyphilis</z:e> could also present with FTD symptoms </plain></SENT>
<SENT sid="9" pm="."><plain>Since FTD requires special clinical care distinct from AD, clinical diagnosis of FTD is quite important </plain></SENT>
<SENT sid="10" pm="."><plain>But for the fundamental treatment based on background pathological processes, surrogate biomarkers, including structural and functional neuroimages and findings of cerebrospinal fluid, blood and urine, should be pursued for future progress in FTD research </plain></SENT>
</text></document>